The pooled dataset included 24 studies and 3,518 patients treated with dual immune checkpoint inhibition for cutaneous or mucosal melanoma brain metastases, the study team reported. Pooled intracranial progression-free survival (iPFS) favored early disease control: 51.9% at 6 months and 44.1% at 12 months. The investigators found continued benefit at later timepoints as well, with pooled iPFS of 40.5% at 2 years and 38.8% at 3 years. These figures represent aggregated results across heterogeneous prospective and retrospective series; the authors used random-effects models to account for between-study variance. Heterogeneity was substantial in some pooled estimates, and long-term signals—particularly the 3-year survival advantage—were noted as less certain because of limited follow-up in several reports.
Across the dual-ICI cohort, the pooled intracranial objective response rate (iORR) was 42.5%. The study team observed a higher pooled iORR—48%—when dual ICI was administered as first-line systemic therapy for brain metastases. Symptom status at treatment start emerged as a clear modifier of outcomes: asymptomatic patients showed superior survival compared with symptomatic patients. Pooled overall survival (OS) at 3 years was 52.3% in asymptomatic cohorts versus 31.5% among symptomatic patients. The authors noted that symptomatic disease continues to represent a clinical challenge and that earlier application of dual ICI may be linked to better intracranial responses.
Safety data across included reports showed a high frequency of adverse events with combination immune therapy. The pooled incidence of any treatment-related adverse event was 78%, while grade 3 or higher events occurred in 48.2% of patients. All-grade immune-related adverse events were reported in 65.5% of patients. The review team emphasized that these toxicity rates align with the known safety profile of combination regimens such as nivolumab plus ipilimumab and call for close monitoring and prompt management of immune-related complications. Several studies that directly reported adverse events for both dual and monotherapy cohorts consistently showed higher rates of both treatment-related and immune-related toxicity with combination therapy.
When data permitted direct comparison, pooled analyses favored dual ICI over ICI monotherapy for overall survival at multiple early and intermediate timepoints. The investigators reported better OS for dual therapy at 6 months, 12 months, and 2 years. By contrast, no statistically significant OS advantage for dual ICI was observed at 3 years in the available pooled comparisons. The authors attributed this divergence to limited long-term data, study heterogeneity, and differences in patient selection across observational and prospective cohorts. They noted that clinicians must weigh the survival benefit seen at early timepoints against the substantially increased toxicity burden associated with combination regimens.
Pooled exploratory analyses examined established prognostic factors. Elevated lactate dehydrogenase (LDH) was associated with worse survival across studies included in the meta-analysis, the authors reported. In contrast, pooled data did not show a significant association between BRAF mutation status and survival outcomes in the dual-ICI population. The source did not provide detailed methodology on how individual studies measured or adjusted for these biomarkers within pooled models; therefore, the review could not specify assay methods, cutoff values, or adjustment covariates across contributing cohorts.
The authors acknowledged several important limitations within their systematic review and meta-analysis. Included studies were a mixture of prospective and retrospective designs, producing clinical and methodological heterogeneity that the random-effects approach could not fully eliminate. Long-term data were sparse in some series, which reduced confidence in the apparent lack of a 3-year survival advantage for dual ICI versus monotherapy. The report did not supply standardized, pooled analyses of dosing regimens, steroid use, prior local therapies, or intracranial lesion burden across cohorts; those details were not consistently reported in source studies and thus could not be meta-analyzed. Finally, symptomatic patients derived less benefit in pooled survival estimates, underscoring an unmet need: effective, tolerable strategies for patients who present with neurologic symptoms remain undefined.
Next steps that the authors signaled as necessary include more consistent prospective data capture on long-term outcomes, toxicity management strategies, and biomarker-standardized analyses to clarify which subgroups derive durable benefit that outweighs the added toxicity. The source did not report specific trial registrations or future regulatory milestones related to these questions.